ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

VSTM Verastem Inc

11.85
-0.07 (-0.59%)
May 10 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 85,623
Bid Price 11.50
Ask Price 11.99
News -
Day High 12.07

Low
4.68

52 Week Range

High
15.18

Day Low 11.65
Company Name Stock Ticker Symbol Market Type
Verastem Inc VSTM NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.07 -0.59% 11.85 18:50:42
Open Price Low Price High Price Close Price Prev Close
11.75 11.65 12.07 11.85 11.92
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,981 85,623 $ 11.84 $ 1,013,448 - 4.68 - 15.18
Last Trade Time Type Quantity Stock Price Currency
18:50:42 15 $ 11.50 USD

Verastem Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
298.74M 25.30M - 0 -87.37M -3.45 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Verastem News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No VSTM Message Board. Create One! See More Posts on VSTM Message Board See More Message Board Posts

Historical VSTM Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week10.4812.1110.4811.54124,2501.3713.07%
1 Month11.7612.119.0210.5992,1870.090.77%
3 Months11.5213.829.0211.61130,8840.332.86%
6 Months6.6814.225.9410.82116,4275.1777.40%
1 Year5.00415.184.6811.30637,6276.85136.81%
3 Years33.8459.223.47422.031,402,476-21.99-64.98%
5 Years15.6059.223.47422.362,146,756-3.75-24.04%

Verastem Description

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers.